Texas GLP-1 Weight Loss Compliance for Med Spas (2026)

Can a Texas Med Spa Legally Run a GLP-1 Weight Loss Program in 2026? The Direct Answer

Yes - under a specific structure. A Texas med spa may lawfully operate a GLP-1 weight loss program in 2026 if it can produce, on demand, four things: a Texas-licensed prescriber with a real relationship to each patient, an FDA-approved GLP-1 product (or a narrowly justified 503A patient-specific compound), a written standing delegation order that authorizes the administering RN or APRN to inject under specified conditions, and a monitoring record that shows the patient was actually followed. Absent any of those four, the program is exposed.

The single biggest change since this page was first written is that the market has shifted from cheap bulk-compounded semaglutide to FDA-approved products. FDA declared the semaglutide shortage resolved on February 21, 2025 and set enforcement deadlines for compounders to stop copying it. Tirzepatide's exemption ended earlier, in the first quarter of 2025, after litigation over the shortage-resolution decision was resolved in FDA's favor. The FDA has since proposed - as of April 30, 2026 - to permanently exclude semaglutide, tirzepatide and liraglutide from the 503B Bulk Drug Substances List, which would close the last realistic bulk pathway. Med spas that built their programs on cash-priced bulk-copy compound semaglutide have had to rebuild them around branded product, tightly justified patient-specific compounds, or shutter the service.

For the national picture, see our complete GLP-1 med spa compliance guide. This page stays inside Texas: Texas Medical Board rules, Texas Board of Nursing scope, Texas State Board of Pharmacy expectations, and how each of them intersects with the federal picture on a Texas floor.

PRESCRIBE: Who Holds Prescriptive Authority for GLP-1s in Texas

GLP-1 receptor agonists are prescription-only. Every legitimate dose that a Texas med spa administers starts with a valid prescription from a person who is authorized to prescribe them. Texas recognises three prescriber roles for this purpose - physicians, advanced practice registered nurses, and physician assistants - and the rules around each are more specific than most spa operators realise.

Physicians (MD and DO)

A physician licensed by the Texas Medical Board may prescribe GLP-1 medications for weight loss to patients they have properly evaluated. There is no separate Texas licence for GLP-1 prescribing, no bariatrics board certification requirement, and no formal "weight-loss physician" registration. The rules that bind the prescribing physician are the same rules that bind any TMB licensee: 22 TAC Chapter 190 (Disciplinary Guidelines), 22 TAC Chapter 174 (Telemedicine), 22 TAC Chapter 165 (Medical Records), and Texas Occupations Code Chapter 164. If the physician also acts as the med spa's medical director, add the delegation rules in 22 TAC Chapter 193 (Standing Delegation Orders) and Chapter 200-series delegation rules.

A physician cannot legitimately prescribe a GLP-1 to a patient they have not evaluated. TMB reads its own rules to require a real practitioner-patient relationship - defined by history, examination, informed consent and documentation - before any first prescription. Signing scripts a nurse or medical assistant "prepared" in advance, in bulk, without touching the chart, is the exact fact pattern that has drawn discipline.

Advanced Practice Registered Nurses (APRNs) and the Prescriptive Authority Agreement (PAA)

Texas is not a full-practice-authority state for APRNs. An APRN (including nurse practitioners) in Texas prescribes controlled and non-controlled drugs, including GLP-1s, only under a written Prescriptive Authority Agreement with a delegating physician, per Texas Occupations Code §§157.0511-.0515. The PAA is not a formality: it must be in writing, must identify the parties, must describe the types of prescriptions the APRN may issue, must set out communication and quality-assurance requirements, and must be reviewed at least annually.

The PAA is filed with the Texas Board of Nursing and the delegating physician's information is on the record with TMB. The delegating physician must actually be reachable and involved. A PAA on paper with a physician who has never met the APRN, does not know what the med spa does, and has no meaningful oversight has been the fact pattern in multiple Texas enforcement actions.

Physician Assistants (PAs)

A PA licensed in Texas may prescribe GLP-1 medications when delegated by a supervising physician under a Prescriptive Authority Agreement - the same PAA vehicle used with APRNs. The delegation is governed by Texas Occupations Code Chapter 157, Subchapter B, and administered by the Texas Physician Assistant Board in conjunction with TMB. As with APRNs, the agreement must describe the drugs and devices the PA may prescribe, the practice locations, communication expectations, and QA requirements.

The Seven-FTE Delegation Cap and Why It Matters for Med Spas

Under Texas Occupations Code §157.0512, a delegating physician may hold Prescriptive Authority Agreements with, and delegate to, no more than seven APRNs or PAs at a time, measured as full-time equivalents. The cap is FTE, not headcount - two half-time PAs count as one - but the number itself is fixed. The statute recognises exceptions for facility-based hospital practices and practices serving medically underserved populations. A retail med spa is not a facility-based hospital practice, and cash-pay weight loss in a metro Texas market is not an underserved-population practice, so the exceptions almost never help a spa.

This becomes a real problem for multi-location med spa groups. If one Texas physician serves as medical director for eight or ten locations, each with a nurse practitioner running the GLP-1 program, the group has silently blown past the cap. TMB has disciplined physicians who over-delegated in exactly this way. If your growth plan involves adding NPs, plan your medical director bench accordingly.

What an APRN Cannot Initiate Alone

An APRN operating under a Texas PAA is not an independent prescriber. The PAA scopes what the APRN can initiate. In practice this means the PAA has to actually list GLP-1 receptor agonists (or the drug class) - a PAA that predates the med spa's weight-loss program and never mentions GLP-1s is not a document under which the APRN can lawfully write those prescriptions. It also means the APRN cannot delegate their delegated authority. What the physician delegated to the APRN, the APRN cannot re-delegate to a medical assistant or an unlicensed staff member. That is the Texas Board of Nursing's stated position and it is a common miss in med spa operations.

The Patient Evaluation Before a First GLP-1 Prescription

The evaluation is what earns the prescription. Texas does not spell out a mandatory GLP-1 pre-prescription checklist by rule, but it does require - under 22 TAC Chapter 190 and the practitioner-patient relationship jurisprudence around TMB - that the evaluation meet the standard of care for initiating chronic pharmacotherapy for weight loss.

Elements TMB Expects in the Initial Evaluation

In practice, the first-visit chart should show at least:

• Chief complaint and history - the patient's weight-loss goals, prior attempts, timeline, and motivation for pharmacologic therapy now.
• BMI and weight trend - documented current weight, height, BMI, and where feasible a documented trend rather than a single snapshot.
• Full medical history - past medical, past surgical, obstetric where applicable, family history focused on medullary thyroid carcinoma and MEN2, personal history of pancreatitis, gallbladder disease, and diabetic retinopathy.
• Full medication and allergy history - including other diabetes agents, other weight-loss drugs, oral contraceptives (absorption interactions), and stated pen or excipient allergies.
• Focused examination - weight, blood pressure, thyroid, abdominal exam.
• Laboratory workup - what the prescriber ordered and why, and either the results or a plan to obtain them before injection.
• Assessment and plan - a written indication for the specific drug chosen, the starting dose, and the titration plan.
• Informed consent - covering on-label vs off-label use for this patient, common and serious adverse effects, monitoring plan, pregnancy warning if applicable, and cost.

Texas has not published a rule that says "the following labs are mandatory." That is a candid gap. But TMB reviewers assess evaluations against the standard of care, and the standard of care for initiating a GLP-1 for weight loss includes at minimum a documented baseline weight, BMI, contraindication screen, and consideration of metabolic labs. Documented consideration is the operative phrase: if you decide not to order a particular lab, chart the clinical reasoning rather than leaving the chart silent.

Can the First-Visit Evaluation Be Done by Telemedicine? 22 TAC Chapter 174 Applied

Yes, under conditions. Texas telemedicine is governed by 22 TAC Chapter 174 (specifically §174.5 for practice standards and §174.6 for practitioner-patient relationship formation and prescribing). A Texas-licensed prescriber may establish the relationship and issue the first GLP-1 prescription by telemedicine when the encounter meets the same standard as an in-person visit.

In practice, this means:

• The provider must be licensed in Texas at the time of the encounter.
• The initial encounter should be synchronous audio-video - not store-and-forward alone, and not a questionnaire.
• The provider must obtain and document the history, contraindication screen, and informed consent in the medical record.
• Prescribing solely based on an asynchronous questionnaire, with no live evaluation, does not satisfy the rule.

The store-and-forward point is the one that catches out-of-state telehealth-first weight loss operators most often. A Texas patient completing an online form, uploading a photo, and receiving a semaglutide prescription in the mail from an out-of-state doctor with no live encounter is the exact pattern TMB has publicly identified as noncompliant.

ADMINISTER: Who May Physically Inject a GLP-1 in a Texas Med Spa

Prescribing is one act. Injecting is a different act, governed by scope-of-practice rules for each licence class. Texas draws lines here that vary meaningfully by injection - even within the same spa.

Registered Nurses (RNs)

Verdict: permissible under a written standing delegation order. An RN may administer a GLP-1 injection to a patient who has a valid prescription from a Texas prescriber, when the RN is acting under a written standing delegation order signed by a delegating physician. The order must be for a specific medication and specific circumstances, must include criteria for who can receive it, must include what to do if the patient reacts adversely, and must be documented in the medical record. This is the standard framework under 22 TAC Chapter 193.

The RN cannot decide the dose escalation on their own. Titration steps that require clinical judgment - move from 0.25 mg to 0.5 mg semaglutide, hold the dose for GI intolerance - must be authorized either in the standing order or by the prescriber for the individual patient. The Texas Board of Nursing has been explicit that RNs may implement orders that do not require independent medical judgment; making the medical decision is not the RN's role.

Advanced Practice Registered Nurses (APRNs)

Verdict: permissible. An APRN with a valid PAA that includes GLP-1 receptor agonists may prescribe and administer the injection. The APRN operating in this role must still document the encounter and the prescriber's rationale in the record. The APRN's authority to inject flows both from the APRN's own scope and from the PAA.

Licensed Vocational Nurses (LVNs)

Verdict: severely limited - do not use as the standard model. A Texas LVN operates under the direct supervision of an RN, APRN, physician assistant, dentist, or physician, and cannot implement protocols that require independent judgment. In a weight-loss program, the recognition of an adverse event, the decision to hold a dose, and the response to a patient reporting acute abdominal pain all require judgment that Texas Board of Nursing views as outside the LVN scope. An LVN may in theory administer a specific injection to a stable patient under direct supervision, but structuring a GLP-1 program around LVN administration is an invitation to a scope violation and is not the defensible model.

Medical Assistants and Unlicensed Personnel

Verdict: do not use for GLP-1 injections in a cosmetic med spa setting. Texas physician delegation law is technically broader than most other states - Texas Occupations Code Chapter 157 allows a physician to delegate certain acts, including some injections, to properly trained unlicensed personnel under direct on-site physician supervision. That statutory permission is real. It is also aggressively narrower in a med spa context than it looks on paper.

TMB treats cosmetic and elective medical services - a category that includes med spa GLP-1 weight-loss programs - as delegated medical acts requiring a licensed nurse or higher in practice. The safer read, and the one plaintiff attorneys and TMB reviewers apply, is that GLP-1 injections in a Texas med spa should be given by an RN, APRN, or physician. Medical assistants can do intake, chart preparation, vitals, and patient education. They should not draw up or inject the GLP-1. Unlicensed staff should not touch the syringe at all.

The Written Standing Delegation Order (22 TAC Chapter 193)

Whatever the RN's or APRN's scope, the paper that lets them do it in your spa is the standing delegation order. In Texas, this is not optional and is not something you can improvise from a manufacturer's sample. The standing order must be:

• Written and signed by the delegating physician, with a date and a review interval (annual at minimum).
• Specific as to drug, dose range, indication, route, and permitted patient population.
• Explicit on contraindications that would prevent administration.
• Explicit on adverse event handling - when to hold, when to escalate to the physician, when to call 911.
• Accessible in the medical record and at the location where the injection is given.

The chart entry for each injection then documents that the RN followed the order for this specific patient. For the wider Texas framework on delegated cosmetic injections, see who can inject Botox in Texas and the delegation rules that apply.

COMPOUND: 503A vs 503B After the Shortage Was Declared Resolved

The compounding question is the one that most drove GLP-1 unit economics from 2022 through 2024, and it is the one that has moved the most in the last eighteen months. Everything below is federal law; Texas overlays TSBP rules on top of it.

What 503A and 503B Mean in One Paragraph

A 503A pharmacy compounds patient-specific prescriptions in response to a valid individual prescription and is regulated primarily by the state board of pharmacy. A 503B outsourcing facility compounds larger volumes without patient-specific prescriptions, is regulated by FDA, and must comply with current good manufacturing practice. Under section 503A of the FDCA, a 503A pharmacy generally cannot compound a copy of a commercially available FDA-approved drug - unless the drug is on the FDA shortage list, in which case an exemption opens. That exemption is what let 503A pharmacies produce compounded semaglutide and tirzepatide starting in 2022. When the shortage ends, the exemption ends.

For the mechanics in depth, see our dedicated page: compounded GLP-1s, 503A and 503B, in 2026. This section stays high-level and Texas-relevant.

What Changed with Semaglutide (February 21, 2025)

FDA announced on February 21, 2025 that the semaglutide shortage was resolved. Recognising that pharmacies could not stop overnight, FDA published enforcement discretion deadlines: 503A pharmacies could continue compounding semaglutide until April 22, 2025, and 503B outsourcing facilities until May 22, 2025. After those dates, an FDA-approved semaglutide product is required unless a narrow 503A exception applies for a specific patient.

What Changed with Tirzepatide (2024 into 2025 and the Lawsuit)

Tirzepatide's timeline was messier. FDA declared the tirzepatide shortage resolved on October 2, 2024. Compounder groups sued. FDA re-reviewed and reaffirmed the decision, and set new enforcement discretion cutoffs: 503A pharmacies had to stop compounding tirzepatide by February 18, 2025 and 503B outsourcing facilities by March 19, 2025. As of August 2026 those deadlines have long since passed.

The April 30, 2026 FDA Proposal on the 503B Bulk Substances List

On April 30, 2026, FDA proposed to exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulk Drug Substances List - the list of substances 503B outsourcing facilities are permitted to compound from bulk absent a shortage. The public comment period ran through June 29, 2026 and the docket remains open at the time of this writing. If FDA finalises the exclusion, the last realistic pathway for bulk-compounding these GLP-1s at 503B facilities will close for good. Med spas planning a 2027 GLP-1 program should assume that outcome is the baseline scenario, not a worst case.

The Narrow 503A Patient-Specific Pathway That Remains

Section 503A allows a licensed pharmacist to compound a drug for an individual patient based on a valid prescription when the compound produces "a change" that produces a significant difference for that patient - for example, when a documented allergy to an excipient in the commercial product requires a formulation without that excipient. This is a real pathway. It is not a business model for a cash-pay weight loss program. Every 503A patient-specific compound of semaglutide or tirzepatide needs a clinical justification in the prescribing chart that would survive TMB review and TSBP inspection. "Patient wanted a lower price" is not a clinical justification.

"Research Peptides" and Non-Pharmacy Suppliers - a Direct Warning

Vials labeled "for research use only" or "not for human use," sold by peptide vendors that are not licensed pharmacies, are neither FDA-approved drugs nor lawfully compounded drugs. Injecting them into a patient is not a compounding question; it is a violation of the Federal Food, Drug, and Cosmetic Act, of TSBP rules for handling drugs, and of the standard of care under TMB rules. The vendor's disclaimer that the product is "not intended for human use" does not create a safe harbour for the prescriber - it removes one. This is the single fastest way for a Texas med spa medical director to lose their licence and to make themselves personally uninsurable. There is no version of this that is legal in Texas.

Texas State Board of Pharmacy Oversight and What to Demand from a Compounder

Even where a compound is federally permissible, TSBP has its own rules for how Texas-licensed compounding pharmacies must operate.

TSBP Licensure and 22 TAC Chapter 291

Texas compounding pharmacies are licensed by the Texas State Board of Pharmacy under Chapter 291 of Title 22 of the Texas Administrative Code, which sets standards for pharmacy operations, labelling, beyond-use dating, and non-sterile and sterile compounding (aligning with USP General Chapters 795 and 797). A Texas med spa sourcing from a Texas pharmacy should be sourcing from a pharmacy whose current TSBP licence and any relevant sterile compounding permit is on file, not one that was licensed once and is now operating under lapsed credentials.

What to Get in Writing from Your Compounder

Regardless of where a compounder sits federally, a Texas med spa should not accept product without documentation. The file for each supplier should include:

• Current TSBP licence and, for out-of-state 503A pharmacies, current licensure with the pharmacy's home state and non-resident licensure in Texas.
• For 503B facilities, current FDA registration as a 503B outsourcing facility.
• The pharmacy's written attestation that its GLP-1 compounding is compliant with current FDA guidance following the resolution of the applicable shortage.
• Certificates of analysis for the active pharmaceutical ingredient with each lot.
• Sterility, endotoxin, and potency test results for each batch of sterile injectables.
• Beyond-use dating on each vial that matches the compound's stability data.
• Insurance information for the compounder, including current product liability limits.

If a Texas pharmacy will not provide any of this, use a different pharmacy. The strongest cases plaintiff counsel bring against med spas after a compounded-drug adverse event turn on the med spa's failure to vet the pharmacy at all. Documentation that the spa did vet the pharmacy - and that the pharmacy actively misled it - shifts liability meaningfully.

Weight Loss Kit — 10 Texas-Ready SOPs

Skip the drafting. Start from Texas-compliant GLP-1 templates.

Intake, contraindication screen, telehealth encounter template, standing delegation order, dose titration record, adverse event response, off-ramp plan — the exact SOPs a Texas GLP-1 program needs on file. $297.

View Weight Loss Kit

MONITOR: The Follow-Up Cadence, Chart Notes, and Off-Ramp

A prescription is not a program. Texas med spa GLP-1 charts that draw negative attention almost always share the same trait: after the first visit, the patient disappears from the chart until refill. What follows is the monitoring skeleton a Texas program should be able to defend at a chart audit.

Baseline Workup and Documentation

Baseline weight, BMI, blood pressure, resting heart rate. Baseline metabolic panel with fasting glucose and HbA1c when the patient's history warrants it. Baseline lipid panel. Consideration of thyroid function testing where clinically indicated. A pregnancy test in patients of childbearing potential before initiation (semaglutide and tirzepatide carry pregnancy warnings). The baseline is what every subsequent visit compares against. Without it, the follow-up notes are floating.

Dose Titration Charting

Every dose change gets a chart entry. For semaglutide, that means at each step (typically 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg for Wegovy) the note captures the current weight, the patient's reported tolerance, whether GI symptoms are controlled, whether any red flags have appeared, and whether the increase is going ahead or the dose is being held. Bulk "titrate as tolerated" language without patient-specific entries is a common finding in TMB reviews. Our GLP-1 monitoring schedule template lays out a compliant cadence you can adapt to a Texas spa; for tirzepatide-specific dosing steps, see the tirzepatide protocol reference.

Follow-Up Cadence

A defensible cadence for the first year on a GLP-1: a check-in at four weeks after the first injection, then a visit at each titration step (every four weeks on the label for semaglutide), then quarterly maintenance visits once the patient reaches their target dose. Visits may be synchronous telehealth per 22 TAC Chapter 174, but each visit is a real encounter with a note, not a refill request stamped by staff. After year one, six-month intervals are reasonable for stable patients; sooner for patients whose weight is fluctuating or who are having adverse effects.

Red-Flag Stop Criteria

The standing order and the patient counselling should both be clear on the events that stop the drug immediately:

• Severe or persistent abdominal pain radiating to the back - rule out pancreatitis.
• New right-upper-quadrant pain, nausea, jaundice - rule out cholecystitis or biliary obstruction.
• Signs of acute kidney injury after significant vomiting or diarrhoea.
• Hypoglycemia in a patient on concomitant insulin or a sulfonylurea.
• New neck mass or hoarseness in a patient not previously known to have a thyroid nodule.
• Confirmed pregnancy.
• Any severe allergic reaction to the injection.

The chart should show the patient received these instructions in writing at initiation and again at each dose change.

Off-Ramping and Maintenance Dosing

A patient who reaches goal weight or who chooses to stop the drug is still under your care during the taper and after. Weight regain after GLP-1 discontinuation is well described in the literature and the spa's off-ramp plan should acknowledge it: a stepped-down dose, a maintenance regimen at a lower step for patients who prefer to stay on, or a documented handoff to a non-pharmacologic maintenance plan. Charts that end abruptly at the last injection - with no follow-up when the patient regains weight and returns - look like the spa was interested only during the paid course.

Contraindications and Screening: MTC, MEN2, Pancreatitis, Pregnancy

Semaglutide and tirzepatide both carry FDA boxed warnings for medullary thyroid carcinoma (MTC) risk based on rodent studies. Personal or family history of MTC, or Multiple Endocrine Neoplasia syndrome type 2 (MEN2), is a contraindication to both drugs. That is not paperwork - it is a first-line screening question, and a chart that does not document that the question was asked is a chart that does not show contraindication screening was done.

The full contraindication and precaution list, at least, includes:

• Personal or family history of MTC.
• MEN2 syndrome.
• Prior serious hypersensitivity to semaglutide, tirzepatide, or any excipient.
• History of pancreatitis - a precaution rather than an absolute contraindication for many prescribers, but one requiring documented clinical judgment before proceeding.
• Pregnancy or planned pregnancy within 2 months of discontinuing (per labelling).
• Severe gastrointestinal disease - relative precaution, particularly for gastroparesis.

Documenting That You Actually Screened

The screening record should be more than a check box. A defensible screen shows: the specific questions asked, the patient's answers verbatim or in structured form, the prescriber's assessment, and the decision to proceed or not. "MTC/MEN2 negative" is thinner than "Patient denies personal or family history of thyroid cancer; no known history of MEN2 syndrome; understands and accepts risk." At an audit, the thicker version reads as due diligence; the check box reads as a form filled out on autopilot.

Adverse-Event Handling and Reporting

Nausea, constipation, and injection-site reactions are common and generally managed with dose adjustment, hydration, and patient education. The events that require more are the ones the standing order and the chart need to be ready for.

For any serious adverse event - acute pancreatitis, gallbladder disease requiring intervention, severe dehydration requiring emergency care, anaphylaxis, thyroid malignancy diagnosis on GLP-1 therapy, death - the following steps should be part of your standard operating procedure:

1. Immediate clinical response. Hold the drug. Escalate to the physician on call. Get the patient to appropriate emergency care.
2. Chart entry. Time-stamped narrative of what happened, what was done, and by whom.
3. FDA MedWatch report. Serious adverse events tied to semaglutide, tirzepatide, or a compounded GLP-1 should be reported to FDA MedWatch. For compounded products, this also gives regulators the pattern data they use to enforce against non-compliant compounders.
4. Manufacturer notification for branded product events.
5. TSBP notification in the case of adverse events tied to a Texas-compounded product, particularly where quality is in question.
6. Insurance carrier notification per your policy's reporting terms.

Documented reporting supports the med spa in a later inquiry. Silence looks like a cover-up. The FDA has publicly noted receipt of hundreds of adverse-event reports linked to compounded semaglutide and tirzepatide in the wind-down period; those reports are among the reasons the compounding exemption is not likely to reopen.

Advertising and Claims: Where TMB, FTC and FDA Rules Bite

Marketing claims are the fastest and cheapest way for a Texas med spa to invite an investigation without ever seeing a patient.

What a Texas Med Spa Cannot Say About Compounded GLP-1s

Do not represent a compounded semaglutide or tirzepatide as being the same as, equivalent to, or a generic version of Ozempic, Wegovy, Mounjaro, or Zepbound. Compounded drugs are not FDA-approved. FDA and FTC treat "same as Wegovy" or "generic Ozempic" claims as deceptive. If your Texas spa is still marketing a compound - within a lawful 503A patient-specific pathway - the marketing should say what it is, not imply it is the FDA-approved product.

Do not promise pounds-per-week, guaranteed results, or before-and-after outcomes untethered from the trial data on the FDA-approved products. FTC has brought enforcement actions against weight-loss operators for exactly these claims, and Texas Attorney General consumer-protection interest tracks federal patterns.

TMB Advertising Rule 22 TAC §164.4

Texas requires physician-owned or physician-supervised advertising to identify the responsible physician and to avoid deceptive claims. For a med spa, that reads onto every landing page, social ad, and email campaign that promotes the GLP-1 program. The physician's name is not hidden compliance paperwork; it is part of the ad. Practices operating as an LLC with a nurse practitioner as the public face and the medical director's name buried in a footer are running the risk pattern TMB has flagged.

Off-Label Marketing

Semaglutide is FDA-approved for Type 2 diabetes (Ozempic), chronic weight management (Wegovy), and cardiovascular risk reduction in certain patients. Tirzepatide is approved for Type 2 diabetes (Mounjaro) and chronic weight management (Zepbound). Marketing Ozempic (a diabetes-indicated product) directly to non-diabetic patients as a weight-loss product is off-label promotion by the prescriber's own name and is a documented enforcement risk. If the spa's program is weight loss, the marketing should describe Wegovy and Zepbound rather than Ozempic and Mounjaro; if the prescriber uses Ozempic off-label, the individual off-label decision goes in the chart, not the ad.

Records, Consent and Retention for a Weight-Loss Program

Texas medical record retention lives at 22 TAC §165.1. The core rule for adults is seven years from the date of the patient's last treatment. For patients under 18, the record must be kept until the patient's 21st birthday or seven years from last treatment, whichever is later. For a GLP-1 program, the "record" is not just the intake form: it includes the initial evaluation, informed consent, standing order the patient was treated under, every telehealth encounter note, every titration entry, every adverse-event report, and any correspondence with the compounding pharmacy or manufacturer if adverse events occurred.

Informed consent for a Texas GLP-1 weight-loss program should be a signed document that covers, at a minimum: the drug being used and whether it is FDA-approved for weight loss or being used off-label; the risks including MTC boxed warning, pancreatitis, gallbladder disease, dehydration and acute kidney injury, hypoglycemia in patients on insulin or sulfonylureas, and the specific pregnancy warning; the monitoring plan; the cost and refund policy; and the patient's understanding that the program is not a guarantee of a specific weight outcome. Consent should be re-executed if the drug or the compounding source changes materially.

What Actually Gets Texas GLP-1 Programs Disciplined: Enforcement Patterns

The theoretical rule map is one thing; the pattern in actual Texas discipline is another. From publicly available TMB disciplinary orders, TSBP enforcement, and pending Texas Attorney General consumer-protection matters against weight-loss operators, the most common findings that end programs (or licences) cluster into six patterns.

Pattern one: no synchronous encounter for a first prescription. Physicians disciplined for prescribing GLP-1s to Texas patients based solely on questionnaires, without a synchronous evaluation. Cited under 22 TAC Chapter 174 and Chapter 190.

Pattern two: over-delegation past the seven-FTE cap. A physician serving as medical director for a multi-location med spa group with more than seven APRN or PA delegatees under active PAAs. Cited under Texas Occupations Code §157.0512.

Pattern three: no standing delegation order for RN administration. RN injecting a GLP-1 under a spa's oral instruction rather than a written physician-signed standing order. Cited under 22 TAC Chapter 193; the RN separately reviewed by the Texas Board of Nursing.

Pattern four: continuing to source compounded semaglutide after the exemption ended. Med spa continued to prescribe bulk-compounded semaglutide after April 22, 2025 without a documented 503A patient-specific clinical justification for each patient. Cited by TMB in the medical-record review; the pharmacy separately by TSBP or FDA.

Pattern five: no monitoring documentation. Charts that show a first visit, a prescription, and nothing until the next refill. Cited under 22 TAC §165.1 and Chapter 190 (standard of care).

Pattern six: use of "research peptides" or unlicensed suppliers. A finding of any vial in the spa's stock labelled "for research use only" or sourced from a non-pharmacy vendor. This tends to be the finding that ends careers rather than just draws a fine. For the broader pattern of what Texas inspectors look for, see Texas med spa inspections and the DSHS compliance violations that recur, and for the specific medical-director responsibilities that get scrutinised, see Texas med spa medical director requirements.

Build-It Checklist: Documents a Compliant Texas GLP-1 Program Must Produce on Demand

If a TMB or TSBP inspector, a plaintiff attorney, or an insurance auditor walked in tomorrow and asked for the GLP-1 program binder, the following files should be pullable inside ten minutes. Every one of them supports one of the rules above.

1. Medical director agreement with the Texas-licensed physician, signed and dated within the year.
2. Prescriptive Authority Agreement (PAA) for each APRN and PA prescriber, listing the GLP-1 drug class explicitly, on file with the Texas Board of Nursing (or the Texas PA Board) and the medical director's TMB record.
3. Physician FTE ledger showing the medical director is within the seven-FTE delegation cap (§157.0512) with the sum-of-FTEs calculation documented.
4. Written standing delegation order for RN administration of each GLP-1, signed by the delegating physician, with the review date.
5. Compounding pharmacy file: TSBP licence, home-state licence for out-of-state 503A pharmacies, FDA registration for 503B facilities, certificates of analysis, sterility results, insurance certificates, and the pharmacy's written attestation on current FDA compliance.
6. Initial patient evaluation template capturing chief complaint, history, MTC/MEN2 screening, pancreatitis history, pregnancy status where applicable, examination, and assessment/plan.
7. Informed consent form covering FDA-approved vs off-label use, MTC boxed warning, pancreatitis, gallbladder risk, dehydration and AKI, hypoglycemia risk with concomitant agents, pregnancy warning, monitoring plan, and cost.
8. Telehealth encounter template compliant with 22 TAC Chapter 174 (synchronous audio-video, documentation of the encounter, prescriber licensure at the time of the encounter).
9. Dose titration record per patient showing weight, tolerance, adverse effects and dose decision at each step.
10. Adverse-event log with MedWatch report copies for any serious events.
11. Advertising archive - saved copies of every landing page and social ad with the responsible physician identified.
12. Records retention policy naming 22 TAC §165.1 and describing the seven-year adult and 21-or-seven-year paediatric rules.

If any file above is missing, the corresponding rule is exposed. Rather than draft each of these from scratch, most Texas med spas start from a ready-to-use med spa SOP and compliance library and tailor each template to their prescriber, medical director, and compounder relationships. Layer that on top of the general framework in our SOP guide for med spas and the common-violation patterns in med spa compliance violations.

The Realistic Picture in Texas for 2026 and Beyond

The Texas GLP-1 market that operated in 2023 and 2024 - large volumes of cheap compounded semaglutide flowing through under-supervised programs - is over. What has replaced it is a smaller, better-priced, and better-documented segment built on FDA-approved product, real clinical evaluations, and prescriber structures that would survive an audit. The programs that pivoted early are more profitable per patient than they were on cash compounds because their patients stay longer and refer more. The programs that did not pivot are either closed or one inspection away from it.

A Texas med spa in 2026 that wants to run GLP-1s should treat every line above as a document to have on file, not advice to consider. The prescriber is a Texas MD, DO, APRN with a valid PAA, or PA. The delegation math sits inside §157.0512. The injections come from an RN under a written standing order. The product is FDA-approved unless there is a patient-specific 503A justification in the chart. The evaluation is real. The monitoring is real. The advertising says what it means. The records are kept for seven years. On that skeleton, a Texas GLP-1 program is a defensible business - and one of the few remaining ways to add meaningful medical revenue to a spa without adding equal legal risk.